In the United States has allowed large-scale clinical trials of ecstasy
Management on products and medicines USA (FDA) approved the conduct of large scale clinical trials of methylenedioxymethamphetamine (MDMA, MDMA, “ecstasy”).
Potential indication for its use was post-traumatic stress disorder (PTSD), writes The New York Times.
MDMA — the psychoactive substance that acts on serotonin, dopamine and noradrenaline receptors in the brain, which different authors klassificeret as a psychostimulant, aporetic or empathogen-entactogen. The ability power to give the perception of the world, people and events a positive spin on it repeatedly and often successfully used in experimental psychotherapy in the 1970-ies.
Read alsoTears of Armenia. History of the Spitak earthquake
After the inclusion of MDMA along with most psychedelics known in the lists of controlled narcotic substances most countries in the world such research virtually ceased. However, in recent years the forces of expert and action groups interest in the potential medical use of these substances began to resume.
One of the areas for the pilot application was PTSD — severe psychological condition that occurs as a result of various traumatic experiences related to violence and suffering, such as military action, natural disasters, terrorist attacks, and others.
Based on the positive results of several previous small studies, the FDA approved the clinical trials phase III (it studied the efficacy and safety of adjusted doses of the drug, the results of which we give a conclusion on the feasibility of clinical application). They will take part in at least 230 patients with PTSD who have not responded to other treatments. Volunteers will conduct psychotherapy in combination with sessions, receiving MDMA in a comfortable environment under the supervision of specialists.
In a previous paper 12 weeks of therapy and three eight-hour session with MDMA, in which the participants shared their traumatic memories with psychologists, led to a decrease in PTSD symptoms on average by 56 percent, and the effect persisted at least throughout the year.
The sponsor conducted and future test stands Multidisciplinary Association of psychedelic studies (MAPS), advocating for the medical use of marijuana, MDMA, LSD, psilocybin and other psychoactive controlled drugs.See alsoCalifornia and Massachusetts voted to legalize marijuana
The organizers of the tests applied to the assignment of MDMA-psychotherapy status “breakthrough treatment” (eng. breakthrough therapy), which, if successful, the study will provide an accelerated introduction of this treatment in clinical practice. In this case we are talking about the year 2021.
Earlier, British researchers have confirmed the efficacy of psilocybin — the active ingredients of hallucinogenic mushrooms of the genus Psilocybe in severe depression. This and similar work was conducted by staff of the Centre of neuropsychopharmacology at Imperial College London, which targets the same MAPS.
He established the famous neuropharmacology and psychiatrist David Nutt (David Nutt John) after his dismissal as head of the Advisory Council on drug abuse at the British Ministry of the interior (ACMD) for public statements exaggerated the dangers of some banned substances.